BSE · VENMAX
Venmax Drugs And Pharmaceuticals Ltd
₹16.08
-3.02%
Operating in Healthcare, Venmax Drugs And Pharmaceuticals Ltd carries a steep earnings multiple that prices in strong future growth, is growing revenue rapidly, and has a subdued return on equity.
Market Cap
—
P/E Ratio
80.40
P/B Ratio
—
ROE
0.76%
ROCE
0.74%
Dividend Yield
—
52W High
₹36.96
52W Low
₹14.10
Quarterly financials
| Metric | Q4 2025-26 | Q3 2025-26 | Q2 2025-26 | Q1 2025-26 |
|---|---|---|---|---|
| Revenue | 3.94 Cr | 1.55 Cr | 1.32 Cr | 1.21 Cr |
| Net Profit | 10.72 L | 3.21 L | 2.44 L | 3.74 L |
| EPS | 0.20 | 0.05 | 0.05 | 0.07 |
| Operating Profit | 1.22 L | -2.53 L | 4.58 L | 3.75 L |
Shareholding pattern
Shareholding pattern for this stock hasn't been ingested yet — check back soon.
Mutual fund holdings
Mutual fund holdings data for this stock hasn't been ingested yet — check back soon.
Recent corporate actions
| Ex-Date | Type | Details |
|---|---|---|
| 29 Jan 2009 | Other | Consolidation of Shares |
| 29 Jan 2009 | Other | Reduction of Capital |
Need this data in your app?
Full price history, technical indicators, and every field above via one REST API call.